- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04746794
Early Detection of GEnetic Risk (EDGE)
Implementing the Moon: Getting Genomic Testing to the Public
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Current practice guidelines from ACMG (American College of Medical Genetics and Genomics) provide referral indications for cancer predisposition assessment. Identifying patients with high genetic risk for breast, ovary, colon, or other cancers has important clinical ramifications for an individual's healthcare, but genetic risk if often not identified because of testing barriers at several levels. Barriers at the provider level include inadequacies in risk recognition, patient referrals and availability of genetic professionals to provide counseling in a traditional testing paradigm. Barriers at the level of the patient include poor understanding of the availability and benefits of testing and inadequate access to testing services. How to best implement appropriate genomic testing and follow-up care into an operating healthcare system is not known. Issues of communication, clinical flow, reportable actions, and transmission of information and support are of critical importance, and must change and grow to accommodate the new information contained within genomic testing. Studies to date of the implementation process have been conducted in high resourced facilities, under optimal conditions, often not at the system level. Aims include:
Compare the efficacy and implementation of two strategies for identifying members of a primary care clinic's population who have a family or personal history of cancer and offering high-risk individuals to obtain genetic testing for cancer susceptibility mutations in a randomized trial. The two methods are: 1) Point of Care (POC) approach: A tablet-based screening for family/personal history of cancer will be offered to all patients aged 25 and up coming in for a routine appointment at the clinic. 2) Direct Patient Engagement (DPE): Letters will be sent to all individuals aged 25 and older in a clinic's population, inviting them to visit a web site for screening for family /personal history of cancer. In both strategies, those determined to be high-risk will receive online education about genetic testing and an invitation to obtain such testing through a web-based platform. Outcomes will be the fraction of the active clinic patient population that completes screening and the fraction of the active clinic patient population that undergoes testing.
Hypothesis 1: DPE screening will result in a higher proportion of active patients who screen for familial cancer risk compared with POC screening.
Hypothesis 2: Of screened patients, POC patients will produce a higher proportion of tested patients compared with DPE.
- Identify changes, problems, and inefficiencies in clinical flow and interactions during and after the implementation of genomic testing for cancer risk across primary care clinics.
- Evaluate the effects of two methods of implementation of genomic screening for cancer risk on patient, provider, and health system leader reports of benefits and harms, satisfaction, perceived quality of care, including across gender, racial/ethnic, socioeconomic, and genetic literacy divides.
- Evaluate the value (cost-effectiveness) and affordability (budget impact) of each screening strategy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Montana
-
Billings, Montana, United States, 59101
- Billings Clinic
-
-
Washington
-
Tacoma, Washington, United States, 98405
- MultiCare Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for Patients:
- Age 25 or older
- An active patient at a participating clinic (had at least one visit in the past 12 months)
- Comfortable reading and writing in English
Exclusion Criteria:
- Those who do not meet inclusion criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Point of Care
In the point of care (POC) arm, patients will be approached at the time they come in to the clinic for a routine visit with their primary care provider.
We will screen patients for familial cancer risk using electronic tablets in the waiting room or, in the case of a telehealth visit, through telephone contact before the visit.
Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers.
|
The study intervention involves having patients complete a familial cancer risk assessment survey.
Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers.
A "previvor" plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified.
|
Experimental: Direct Patient Engagement
In the direct patient engagement (DPE) arm, patients will be identified by reviewing clinic records to create an "active" patient list (i.e., those who have had a visit in the past year).
We will contact patients by postal mail and email to provide a link to the online risk screening tool.
The patient outreach is not tied to a specific visit and the online screening can be completed at any time.
Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers.
|
The study intervention involves having patients complete a familial cancer risk assessment survey.
Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers.
A "previvor" plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified.
|
No Intervention: Stakeholder Interviews and Surveys
Samples of patients, providers, and clinic leaders will be assessed at several points throughout the study - baseline and multiple follow-ups.
We will use a mixed methods approach, with both quantitative assessments (surveys) and qualitative assessments (interviews).
Baseline assessments will provide initial data on the patient population and current clinic functioning and help in implementation planning.
The midpoint and final assessments will provide estimates of change in patients, providers, and clinic leaders as a result of the implementation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rates of screening
Time Frame: 1.5 years
|
Fraction of the active clinic patient population that completes screening
|
1.5 years
|
Rate of testing
Time Frame: 1.5 years
|
Fraction of the active clinic patient population that undergoes testing.
|
1.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Implementation barriers on the clinic-level
Time Frame: 1.5 years
|
To identify changes, problems, and inefficiencies in clinical flow and interactions during and after the implementation of genomic testing for cancer risk across primary care clinics.
|
1.5 years
|
Genetic Literacy and Comprehension (GLAC)
Time Frame: up to 2 years
|
GLAC scale for genetic literacy.
|
up to 2 years
|
Implementation Leadership Scale (ILS)
Time Frame: up to 2 years
|
ILS scale.
|
up to 2 years
|
Implementation Climate Scale (ICS)
Time Frame: up to 2 years
|
ICS scale.
|
up to 2 years
|
Organizational Readiness to Change Assessment (ORCA)
Time Frame: up to 2 years
|
ORCA scale.
|
up to 2 years
|
Intervention characteristics (ex: evidence strength and quality)
Time Frame: up to 2 years
|
Self-developed measure.
|
up to 2 years
|
Trust in Physician Scale (TIPS)
Time Frame: up to 2 years
|
TIPS scale for Physician trust.
|
up to 2 years
|
Patient Satisfaction Questionnaire Short-Form (PSQ-18)
Time Frame: up to 2 years
|
PSQ-18
|
up to 2 years
|
Communication with family members
Time Frame: up to 2 years
|
Self-developed measure.
|
up to 2 years
|
Reasons for completing (or not completing) genetic testing
Time Frame: up to 2 years
|
Self-developed measure.
|
up to 2 years
|
Reasons for completing (or not completing) screening.
Time Frame: up to 1.5 years
|
Self-developed measure.
|
up to 1.5 years
|
Quality of life scale
Time Frame: up to 1.5 years
|
Self-developed measure to measure patient quality of life.
|
up to 1.5 years
|
Health literacy
Time Frame: up to 1.5 years
|
Self-developed measure patient's health literacy.
|
up to 1.5 years
|
Cost-benefit analysis - cost-effectiveness
Time Frame: up to 5 years
|
Sel-developed measure to evaluate the value (cost-effectiveness) at each site
|
up to 5 years
|
Cost-benefit analysis - budget impact
Time Frame: up to 5 years
|
Self-developed measure to measure the affordability of each screening strategy at each site
|
up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Elizabeth M Swisher, MD, University of Washington
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00009476
- 1U01CA232795-01A1 (U.S. NIH Grant/Contract)
- RG1123410 (Registry Identifier: Fred Hutch/University of Washington Cancer Consortium)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genetic Predisposition
-
National Cancer Institute (NCI)RecruitingCancer | Hereditary Neoplasms | Genetic Predisposition to Cancer | EnvironmentUnited States
-
St. Jude Children's Research HospitalRecruitingGenetic PredispositionUnited States
-
MedneonEnrolling by invitation
-
Eunice Kennedy Shriver National Institute of Child...CompletedGenetic PredispositionUnited States
-
University of VirginiaCompleted
-
Children's Hospital of PhiladelphiaNational Institutes of Health (NIH); National Human Genome Research Institute...Recruiting
-
University of VirginiaActive, not recruiting
-
The University of Texas Health Science Center at...Not yet recruiting
-
Centre Georges Francois LeclercRecruitingCancer | Genetic PredispositionFrance
-
St. Jude Children's Research HospitalCompletedPediatric Cancer | Predisposition, GeneticUnited States
Clinical Trials on Population-level screening
-
Todos Medical, Ltd.Unknown
-
University of ManitobaBoehringer Ingelheim; Research Manitoba; First Nations Health and Social Secretariat... and other collaboratorsNot yet recruitingKidney Disease, Chronic
-
Magentiq Eye LTDCompleted
-
University of California, DavisNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
University of Alabama at BirminghamCompleted
-
University of KentuckyNational Cancer Institute (NCI); Ohio State UniversityRecruitingColorectal CancerUnited States
-
Institute of Tropical Medicine, BelgiumSciensanoCompletedHIV InfectionsBelgium
-
Assistance Publique - Hôpitaux de ParisMerck Sharp & Dohme LLCRecruitingPulmonary Embolism | Chronic Thromboembolic Pulmonary Hypertension (CTEPH)France
-
M.D. Anderson Cancer CenterActive, not recruitingPediatric CancerUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingVaccinationsUnited States